A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

NCT05433194 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: ABO1009-DP

Sponsor

Suzhou Abogen Biosciences Co., Ltd.